210 related articles for article (PubMed ID: 24125873)
1. Bone marrow leukaemic transformation of myelodysplastic syndrome revealed by a cutaneous Langerhans cell infiltrate: partial response to azacitidine.
Osio A; Elfatoiki F; Raffoux E; Vignon-Pennamen MD; de Labarthe A; Cordoliani F; Petrella T; Bagot M; Janin A; Battistella M; Bouaziz JD
Eur J Dermatol; 2013; 23(5):710-1. PubMed ID: 24125873
[No Abstract] [Full Text] [Related]
2. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
[No Abstract] [Full Text] [Related]
3. [Myelodysplastic syndrome--its natural history, clinical course and diagnosis].
Weryńska B
Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):867-71. PubMed ID: 2487939
[No Abstract] [Full Text] [Related]
4. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
Pinto A; Zagonel V; Attadia V; Bullian PL; Gattei V; Carbone A; Monfardini S; Colombatti A
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():28-32. PubMed ID: 2483349
[No Abstract] [Full Text] [Related]
5. Acute myeloblastic leukemia.
Molina CA; Rodríguez MJ; de Marcos NS; Font P
Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
[TBL] [Abstract][Full Text] [Related]
6. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
7. Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
Villela L; Anders V; Bolaños-Meade J
Anticancer Drugs; 2010 Apr; 21(4):469. PubMed ID: 20216343
[No Abstract] [Full Text] [Related]
8. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
[No Abstract] [Full Text] [Related]
9. Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
Font P
Adv Ther; 2011 Mar; 28 Suppl 3():1-9. PubMed ID: 21431628
[TBL] [Abstract][Full Text] [Related]
10. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
12. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
[No Abstract] [Full Text] [Related]
13. [CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Schleiffenbaum BE
Praxis (Bern 1994); 2014 May; 103(11):617-27. PubMed ID: 24846886
[No Abstract] [Full Text] [Related]
14. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
Omatsu T; Udaka K; Shibata H; Sekimoto E; Ozaki S
Rinsho Ketsueki; 2017; 58(12):2369-2374. PubMed ID: 29332868
[TBL] [Abstract][Full Text] [Related]
15. [Clinical picture and molecular disorders in myelodysplastic (MDP) syndromes].
Rupniewska ZM
Pol Arch Med Wewn; 1992 Mar; 87(3):197-208. PubMed ID: 1523148
[No Abstract] [Full Text] [Related]
16. MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.
Krejcik Z; Belickova M; Hrustincova A; Votavova H; Jonasova A; Cermak J; Dyr JE; Merkerova MD
Cancer Biomark; 2018; 22(1):101-110. PubMed ID: 29630523
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous myeloid dendritic cell dyscrasia: A cutaneous clonal monocytosis associated with chronic myeloproliferative disorders and peripheral blood monocytosis.
Magro CM; Momtahen S; Verma S; Abraham RM; Friedman C; Nuovo GJ; Tam W
Ann Diagn Pathol; 2016 Dec; 25():85-91. PubMed ID: 27806853
[TBL] [Abstract][Full Text] [Related]
18. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H
Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582
[No Abstract] [Full Text] [Related]
19. Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence.
Niscola P; Tendas A; Cupelli L; Neri B; Scaramucci L; Morino L; Giovannini M; Fratoni S; de Fabritiis P
Support Care Cancer; 2013 Feb; 21(2):365-6. PubMed ID: 22960853
[No Abstract] [Full Text] [Related]
20. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
[Next] [New Search]
